- Home
- HOFT vs ZNTL Comparison
HOFT vs ZNTL Comparison
Compare HOFT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- ZNTL
- Stock Information
- Founded
- HOFT 1924
- ZNTL 2014
- Country
- HOFT United States
- ZNTL United States
- Employees
- HOFT N/A
- ZNTL N/A
- Industry
- HOFT Home Furnishings
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- HOFT Consumer Discretionary
- ZNTL Health Care
- Exchange
- HOFT Nasdaq
- ZNTL Nasdaq
- Market Cap
- HOFT 109.2M
- ZNTL 105.8M
- IPO Year
- HOFT 1999
- ZNTL 2020
- Fundamental
- Price
- HOFT $9.48
- ZNTL $1.64
- Analyst Decision
- HOFT
- ZNTL Buy
- Analyst Count
- HOFT 0
- ZNTL 6
- Target Price
- HOFT N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- HOFT 64.6K
- ZNTL 686.7K
- Earning Date
- HOFT 09-11-2025
- ZNTL 11-11-2025
- Dividend Yield
- HOFT 9.77%
- ZNTL N/A
- EPS Growth
- HOFT N/A
- ZNTL N/A
- EPS
- HOFT N/A
- ZNTL N/A
- Revenue
- HOFT $376,278,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- HOFT N/A
- ZNTL N/A
- Revenue Next Year
- HOFT $15.15
- ZNTL N/A
- P/E Ratio
- HOFT N/A
- ZNTL N/A
- Revenue Growth
- HOFT N/A
- ZNTL N/A
- 52 Week Low
- HOFT $7.34
- ZNTL $1.01
- 52 Week High
- HOFT $19.79
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- HOFT 37.58
- ZNTL 50.91
- Support Level
- HOFT $9.12
- ZNTL $1.54
- Resistance Level
- HOFT $10.74
- ZNTL $1.69
- Average True Range (ATR)
- HOFT 0.53
- ZNTL 0.09
- MACD
- HOFT -0.19
- ZNTL 0.00
- Stochastic Oscillator
- HOFT 4.23
- ZNTL 54.35
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.